RxDoctor Payments Data

Philippe Bulauitan, MD

Family Medicine · Raleigh, NCNPI 1609168988

Payments from drug & device makers

$5,494in general payments, 2019–2025

Across 305 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Gilead$724
  • AbbVie$648
  • Lilly USA, LLC$602
  • GSK$371
  • AstraZeneca$364
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,494 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,536
Medicare patients
85
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$71,517
FarxigaDapagliflozin Propanediol17$24,120
JardianceEmpagliflozin13$21,768
EliquisApixaban15$17,643
AbrysvoRsv Vacc, Pref A And Pref B/Pf16$5,145
Breo ElliptaFluticasone/Vilanterol13$5,019
SynthroidLevothyroxine Sodium17$1,945
Atorvastatin Calcium140$1,845
Rosuvastatin Calcium65$902
Albuterol Sulfate HfaAlbuterol Sulfate30$801
Levothyroxine Sodium50$798
Duloxetine Hcl31$735
Tamsulosin Hcl43$613
Losartan Potassium64$535
Pantoprazole Sodium34$534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,142$71,51747 claims
AstraZenecaFarxiga$364$24,12017 claims
PfizerEliquis, Abrysvo$277$22,78931 claims
Boehringer IngelheimJardiance$52$21,76813 claims
GSKBreo Ellipta$371$5,01913 claims
AbbVieSynthroid$648$1,94517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →